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Summary: Chemical genetics, or chemical biology, has
become an increasingly powerful method for studying
biological processes. The main objective of chemical
genetics is the identification and use of small molecules
that act directly on proteins, allowing rapid and reversi-
ble control of activity. These compounds are extremely
powerful tools for researchers, particularly in biological
systems that are not amenable to genetic methods.
In addition, identification of small molecule interactions
is an important step in the drug discovery process.
Increasingly, the African frog Xenopus is being used for
chemical genetic approaches. Here, we highlight the
advantages of Xenopus as a first-line in vivo model
for chemical screening as well as for testing reverse
engineering approaches. genesis 00:1–12 , 2012. VC 2012
Wiley Periodicals, Inc.
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WHAT IS CHEMICAL GENETICS?
Chemical genetics is the identification of small mole-
cules that can be used to study any biochemical or phys-
iological process of interest. In this method, chemical
tools are used to manipulate protein activity, providing
the ability to analyze complex, multicomponent biologi-
cal processes over time (Walsh and Chang, 2006). For
developmental biologists, current genetic methods pro-
vide limited temporal control; thus, chemical genetics
can offer a complementary approach to loss-of-function
mutations.
Chemical genetics, like classical genetics, makes use
of forward and reverse approaches. Forward analyses
are modeled on classical genetic screens in which the
search is driven by a phenotype of interest. Reverse
screens are designed to target proteins of interest,
either by searching for specific drug–protein interac-
tions or by engineering chemically sensitive proteins.
Large-scale mutagenesis screens using genetic model
systems have been used very successfully for many years
in identifying genes involved in developmental and physi-
ological events. However, such screens are expensive
and time consuming. In addition, with respect to later
development and organogenesis, these screens can be
limited in scope. During embryonic development, many
patterning and signaling systems are used multiple times
(Davidson et al., 2002; Reya and Clevers, 2005; Van Raay
and Vetter, 2004). Thus, if an embryo is disrupted at an
early time point because of a mutation, later events using
the same pathway become difficult to study. Such muta-
genesis screens therefore do not allow for the assessment
of the finer temporal control of protein function. The
ability to have temporal control over compound addition
and thus the modulation of protein function provides a
more focused approach to phenotypic assays. This also
means that chemical genetic screens are applicable to
maternal proteins, which many traditional mutagenesis
screens are not, significantly extending the opportunity
to identify key endogenous players in biological
processes.
Chemical genetic screens have been done on many
organisms (Wheeler et al., 2011). In this review, we
focus on the increasing use of Xenopus laevis for small
molecule screening. We will also discuss recent devel-
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opments in synthetic chemical genetics and the poten-
tial use of Xenopus for first-line in vivo validation.
Setting up chemical genetic screens
There are two purposes for carrying out phenotypic
chemical genetic screens in model organisms. One is to
promote research in a given area by obtaining small
molecules that can be used to investigate fundamental
questions, and the other is as a screen for pharmaceuti-
cal reagents that potentially can be used for clinical
purposes.
The initial step of a chemical genetic screen is to
design an assay or identify a phenotype that will be the
target for the screen and to choose the relevant model
organism. The screen could be to identify morphologi-
cal or behavioral changes in the organism as well as
alterations in gene expression. Traditional expression
screens have previously demonstrated the power, ease
and flexibility of Xenopus for the identification of gene
function (Grammer et al., 2000). Morphological
changes, such as axis formation, apoptosis, and edema
are readily scored by eye. Tadpoles can then be proc-
essed for mRNA by in situ hybridization or protein by
antibody staining. Current screening protocols can
include use of tissue-specific transgenic lines such as
eye-specific green fluorescent protein (GFP) reporter
levels, in situ hybridization, microarray technology, or
deep sequencing. This two-tiered approach has been
nicely demonstrated in a recent study by Kalin et al.
who identified a number of molecules involved in angio-
genesis (Kalin et al., 2009).
Once the assay has been designed, a library of com-
pounds is chosen. There are many sources for such
libraries as discussed in Wheeler and Brandli, 2009. Of
course, the choice of the library depends on the
researchers’ initial goals and will greatly affect the na-
ture of the positive hits. For example, the screen may
be designed to test analogs of known compounds with
identified target proteins [e.g., screening a library of py-
rimidine-based Wnt agonists, (Liu et al., 2005)]. Alterna-
tively, the screen could be designed with a functional
goal [e.g., disruption of thyroid hormone function, (Fini
et al., 2007)]. Finally, the screen could be designed with
a biological process in mind [e.g., molecules that affect
melanocyte development, (Tomlinson et al., 2009a)].
Some recent examples of chemical screens using Xeno-
pus are shown in Table 1.
Once the screen has been carried out and hits
obtained, these hits need to be validated. This can be
done in a number of ways including determining the
mechanism of action, identifying potential targets, and
testing for interactions. Compound effects can be
assessed in secondary assays or by showing similar
effects in other organisms. Validation of drug–protein
interactions is likely the most challenging part of this
procedure. Specificity and off-target effects can also be
difficult to assess. Use of Xenopus can improve the effi-
ciency of validation: first, perturbations of conserved
signaling pathways leads to stereotypical phenotypes
which are well documented, and, second, overexpres-
sion of a putative protein target in Xenopus can
allow the researcher to do simple ‘‘competition’’ assays.
Table 2 gives some examples of functional validation
carried out using Xenopus.
Table 1
Large Scale Chemical Screens Using Xenopus for In Vivo Phenotyping
Assay Library No. of compounds Reference
Pigmentation Diversity Set, NCI 1990 Tomlinson et al., 2009
Gen-Plus, Microsource 960 Tomlinson et al., 2009
Angiogenesis/lymphangiogenesis LOPAC, Sigma–Aldrich 1280 Kalin et al., 2009
TGF-b inhibitor/heterotaxia Novel compounds 130 Dush et al., 2011
Table 2
Examples of Functional Validation of Chemical Screens Using Xenopus
Activity Compound(s) Target(s) Reference
Inhibition of Wnt reporter lines CCT036477 unknown Ewan et al., 2010
In vitro stabilization of Axin pyrvinium CK1 Thorne et al., 2010
GSK-3 inhibition BIO GSK-3 Meijer et al., 2003
Wnt inhibition JW67 unknown Waaler et al., 2011
JW74
Wnt agonist QS11 ARFGAP Zhang et al., 2007
Wnt agonist 2-amino-4,6-disubstituted pyrimidine unknown Liu et al., 2005
Dishevelled inhibition NSC668036 Dsh-PDZ Shan et al., 2005
Dishevelled inhibition 3289–8625 Dsh-PDZ Grandy et al., 2009
b-catenin-dependent transcription PKF115–584 TCF/b-catenin interactions Lepourcelet, 2004
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The Xenopusmodel and why it is a useful
addition to chemical genetics
Xenopus has a long history in the fields of develop-
mental biology, teratology and toxicology but is rela-
tively new to chemical genetics. Frog Embryo Terato-
genesis Assay–Xenopus (FETAX) is an assay used for
many years to screen for effects of known chemicals on
early developmental stages (Longo et al., 2008; Richards
and Cole, 2006) and protocols exist to study the effects
of small molecules on metamorphosis. However, until
recently, chemical genetic screens had not been carried
out in Xenopus embryos, and screens using zebrafish
have led the way in vertebrates. In recent years, the use
of genetics in Xenopus tropicalis (Goda et al., 2006)
and work by the authors and others in chemical genetic
phenotypic screens have shown Xenopus to be an
excellent model system for such screens (Adams and
Levin, 2006; Longo et al., 2008; Tomlinson et al., 2005,
2009a; Wheeler and Brandli, 2009). In fact, Xenopus is
the only tetrapod vertebrate to have free-living embryos
in which embryonic development is neither in utero
nor in ovo and thus is the highest order in which high-
throughput screens can be carried out (Wheeler and
Brandli, 2009).
Xenopus has many of the advantages that are neces-
sary to carry out phenotypic screens. Its eggs can be
easily obtained in large numbers at any time during the
year by simple hormone injection, and they can then be
synchronously fertilized. This facilitates biochemical,
pharmacologic, and statistical analyses. The embryos
develop in the petridish in simple salt solutions at room
temperature. X. laevis embryos are bigger than zebra-
fish but can still be screened in 96-well plates (Tom-
linson et al., 2005, 2009a; Wheeler and Brandli, 2009).
Compounds can be added to the media, and the vitel-
line membrane around the embryo is highly porous and
accessibility of compounds to the embryo is usually
good. Moreover, Xenopus embryos are easy to microin-
ject so cell-impermeable compounds can also be simply
tested in vivo. In addition, the detailed fate map for Xen-
opus facilitates injection of compounds, as they can be
easily targeted to specific areas of the embryo (Dale and
Slack, 1987). This is not the case with zebrafish, in
which cell migration and mixing during gastrulation
prevent targeted injections.
Also unique to Xenopus among model organisms is
the use of Xenopus oocytes as ‘‘laboratories’’ for the
study of ion translocators, neurotransmitter receptors,
second messenger cascades, calcium-dependent events,
and cytoskeletal rearrangements (examples of screens
include Peterson et al., 2001; Verma et al., 2004;
Wignall et al., 2004). In addition, Xenopus oocyte and
egg extracts are used extensively to study DNA damage
and cell cycle progression (Peterson et al., 2006; Dupre
et al., 2008). As a result, chemical screens making use
of these biochemical properties of Xenopus have been
particularly successful. However, using Xenopus for in
vivo chemical screening is a comparatively recent devel-
opment (Tables 1 and 2).
Forward screens using Xenopus
The Wheeler and Brandli labs have shown Xenopus
to be a useful model for developmental chemical
genomic screens (Bra¨ndli, 2004; Tomlinson et al.,
2005).
Figure 1a outlines how we do a large-scale screen
with Xenopus embryos. A full description of the meth-
odology can be found in Tomlinson et al. (2012). Unless
interested in specific early developmental effects or gas-
trulation phenotypes, we apply compounds postgastru-
lation. Our previous studies have shown that the degree
of nonspecific toxicity of compounds is much lower if
applied at this time (Tomlinson et al., 2005). Embryos
are viewed under a low-magnification dissecting micro-
scope. Phenotypes easily scorable include pigmenta-
tion, effects on the eye (i.e., small eye) and effects on
shape of the head, body, and fin (Fig. 1b).
In forward screens, it is important to target a specific
phenotype or organ to identify compounds with
defined, specific effects or modes of action. Mutagene-
sis screens often examine a phenotype of the whole
embryo. For instance, in Drosophila, phenotypic
changes in the outer cuticle pattern led to insight into
important patterning and morphogenesis pathways
(Nusslein-Volhard and Wieschaus, 1980). In some of the
initial Xenopus screens, pigmentation was looked at, as
changes in pigment pattern of the embryo are easily
scorable. Pigment cells are derived from pluripotent
neural crest cells and can give rise to melanoma. So
effects on pigment can relate to issues of neural crest
induction, cell morphology, cell migration, cell bio-
chemistry, as well as cancer biology (Blackiston et al.,
2011; Tomlinson et al., 2009a,b; White et al., 2011).
In our screen we identified a number of compounds
that affect pigment cell migration (Tomlinson et al.,
2009a). Further analysis of one of these showed it to be
a novel matrix metalloproteinase (MMP) inhibitor (Tom-
linson et al., 2009b). MMPs are a family of proteins
known to have important roles in cell migration, inflam-
mation, angiogenesis, and cancer (Page-McCaw et al.,
2007). Another compound (NSC210627) was character-
ized as an inhibitor of dihydroorotate dehydrogenase
(DHODH). This led to the identification of leflunomide,
a structurally distinct DHODH inhibitor, which phe-
nocopied NSC210627 in Xenopus and zebrafish. Other
compounds were also identified that affect pigment cell
morphology, and the production of pigment and their
cellular targets have begun to be determined (Tom-
linson et al., 2009a). In a powerful validation of this
approach, subsequent tests on melanoma cell lines and
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in vivo mouse models showed leflunomide to be a
potent inhibitor of melanoma growth (White et al.,
2011). Human clinical trials are now underway.
In another screen small molecule regulators of lym-
phatic and blood vascular system development were
identified (Kalin et al., 2009). Interestingly, when the
same library was used on zebrafish the screen identified
fewer of the antiangiogenic compounds known to be in
the library than the Xenopus screen thus suggesting
Xenopus could be more sensitive in recovering com-
pounds with vascular activity.
A recent study identifying the TGF-b inhibitor hetero-
taxin nicely illustrates the power of Xenopus for in vivo
screening (Dush et al., 2011). The establishment of the
left-right axis in vertebrates is dependent on TGF-b sig-
naling. In Xenopus, phenotypic readouts of TGF-b inhi-
bition are well established; heterotaxia (reversal of
organ laterality) was easily scored by examining looping
of the heart and guts. In addition, molecular and bio-
chemical consequences of TGF-b perturbation were
also easily assessed by expression analysis and western
blotting. Although the authors do not identify the direct
drug–protein interaction in this study, they place the
action upstream of the Smad2 phosphorylation. We
expect future studies could include testing TGF-b
receptors and ligands in competition with heterotaxin,
which may be able to distinguish selectivity of the
compound.
Screening with random libraries has its advantages
and disadvantages. Random libraries are unbiased and
may reveal novel compounds or novel pathways. How-
ever, screening with random libraries can rapidly
become unwieldy. How does one limit the number of
compounds screened? It is possible to screen pools of
compounds as shown by Dush et al. (2011). But, this
may limit the efficacy of each individual molecule and
obscure its function. Furthermore, identification and
validation of protein interactions can be particularly
difficult, as target proteins are usually unknown.
Additional means are often necessary, as in a recent
cell culture study designed to identify compounds that
antagonize Wnt signaling. Huang et al. used affinity
capture experiments in which the compound
(XAV939) was immobilized and used as molecular
‘‘bait,’’ thus identifying tankyrase as a target protein
(Huang et al., 2009). When using Xenopus, one could
imagine subsequent analyses would then include
experiments examining tankyrase itself (Chang et al.,
2005; Liu et al., 2005).
Targeted screens with small libraries of compounds
of a known functionality are also powerful. An example
of this is the recent use of histone deacetylase (HDAC)
inhibitors to show that HDAC activity is required for
left-right patterning (Carneiro et al., 2011). Because
Xenopus is quite amenable to whole animal analyses,
this approach can uncover previously unknown pheno-
types for specific protein activities.
Levin et al. have also developed an interesting chemi-
cal genetic strategy using Xenopus (Levin et al., 2006).
They use known pharmacologic compounds to corre-
late specific families of proteins with a chosen biologi-
cal phenotype. They have taken advantage of a hierarch-
ical structure that can be shown for drug reagents in a
number of fields, such as ion transport, neurotransmit-
ter function, metabolism, and the cytoskeleton. They
call this an ‘‘inverse drug screen’’ (Levin et al., 2006).
The advantage is that it is more efficient than carrying
out an exhaustive screen with large numbers of drugs
and instead quickly reveals a manageable number of
specific molecular candidates that can then be validated
and targeted. They have used this method to determine
whether the ion flow was important for embryonic left/
right patterning (Adams and Levin, 2006; Adams et al.,
2006) and to uncover novel prenervous system roles for
FIG. 1. Screening chemical libraries using Xenopus. (A) Chemical libraries are arrayed in 96-well plates. Multiple tadpoles can be
cultured in each well and are added at a stage of interest. Tadpoles are then cultured until desired maturity. (B) The transparency of the free-
swimming tadpoles allows easy assessment of a variety of organs some examples of which are shown.
4 WHEELER AND LIU
the neurotransmitter serotonin (Fukumoto et al., 2005;
Levin et al., 2006). They first test for a specific pheno-
type using known global inhibitors of a cellular func-
tion, that is, ion transport. If this causes a phenotype,
they then test more specific drugs that target subset
pathways of this global inhibitor. Thus, they use a gen-
eral ion channel inhibitor to show a phenotype and
then narrow this down to a specific ion channel or
pump (Adams and Levin, 2006). Recently they have also
used ion channel drugs to identify new cell types
(Blackiston et al., 2011).
Future screens that can be or are being done will
make use of Xenopus’ evolutionary proximity to mam-
mals. Therefore, screens looking at aspects of limb
development and regeneration (in the eye, tail, or limb)
can be envisaged. Assay systems are also being devel-
oped to screen for compounds that affect learning and
behavior (Blackiston et al., 2010).
Reverse engineering of chemically dependent
systems
As described above, broad chemical screening meth-
ods are very useful. However, one drawback is that
target specificity can be difficult to validate, particularly
if the initial chemical library contains a broad range of
compounds, rather than compounds chosen in a phar-
macophore or similarity screen. In addition, drug dis-
covery approaches are most readily applied to enzymes,
which have clear active sites for targeting inhibition.
Many other proteins, such as transcription factors or
structural proteins are hard to regulate in this fashion.
As a result, chemical screens can be difficult to general-
ize. Recently, rationally designed methods have become
more widespread and developmental biologists are
adapting these synthetic strategies to regulate specific
protein activities (Nielsen and Schreiber, 2008).
Ideally, drug–protein interactions should be highly
specific, with no off-target effects, and function should
be regulated rapidly and reversibly. Demonstrating spec-
ificity, or eliminating the possibility of off-target effects,
is difficult. However, this is also a problem that arises
with open-ended screening described above. The best
test for specificity is comparison with a genetic mutant
(Liu et al., 2007). However, this is often impossible.
Although not ideal, the ease of knockdown and overex-
pression in Xenopus often provides a good correlation
with specificity. As a result, Xenopus assays are fre-
quently used to validate compounds that affect Wnt and
other pathways (Liu et al., 2005; Meijer et al., 2003).
The drug–protein interaction will also ideally be rapid
and reversible; in some cases, competitive inhibitors
can be used to test both speed and reversibility, as with
small molecule effectors of Hedgehog signaling (Frank-
Kamenetsky et al., 2002).
Finally, for generality, the approaches should be appli-
cable to a wide range of targets. For example, the Sho-
kat lab recently designed a system in which a single
amino acid substitution in the kinase domain of the Trk
receptor results in inhibition of the receptor by a small
molecule inhibitor PP1 (Chen et al., 2005). The Ginty
and Shokat labs then produced Trk-A knock-in mice that
could be combined with a PP1 analogue for rapid, spe-
cific and reversible inhibition of TrkA in vivo (Chen
et al., 2005). In principle, this approach could be easily
generalized; however, to our knowledge, this strategy
has not yet been applied to Xenopus studies.
Controlling transcription with small molecules
As noted above, proteins such as transcription factors
are notoriously difficult to target chemically (compare
to kinases, above, which have clear active sites).
Researchers frequently bypass this problem by fusing
transcription factors with small-molecule-sensitive moi-
eties. In a method that is now routine in Xenopus, the
ligand-binding domains of hormone receptors such as
the glucocorticoid (GR), estrogen and ecdysone recep-
tors can be fused to transcription factors. In the
absence of ligand, these chimeric proteins are seques-
tered. Ligand binding induces a conformational change
in the protein, uncovering nuclear localization signals
(Fig. 2a). This approach, initially developed for in vivo
use by Kolm and Sive in 1995, has been very successful
for ligand-dependent transcriptional activation (Kolm
and Sive, 1995, summarized in Table 3). In Xenopus,
fusion constructs can be easily expressed as mRNA and
injected into specific tissues, allowing tissue and tempo-
ral analysis of transcription factor targets. When com-
bined with activator (VP16) or repressor (engrailed)
fusions, this system can be used to turn transcription
factor targets on or off in response to the drug dexa-
methasone (Horb and Thomsen, 1999; Rones et al.,
2000). Further refinement of this system makes use of
GR fusions with a yeast transcriptional activator, Gal4,
which recognizes an upstream activating sequence
(UAS) that is absent in vertebrates. Hartley et al. had
previously demonstrated the utility of Gal4-UAS systems
in stable Xenopus transgenics (Hartley et al., 2002).
Transgenic animals are then produced carrying two
plasmids, one encoding the Gal4-GR fusion and the sec-
ond carrying the UAS driving expression of the target
gene. In principle, a tissue-specific promoter could be
used to drive expression of the Gal4-GR fusion protein
[Fig. 2b, (Hartley et al., 2002)]. Tissue-specific trans-
genic lines have also been developed for Xenopus tropi-
calis using Gal4-progesterone receptor fusions
(GAL4PR) which can be induced using low doses of the
synthetic progesterone analogue RU486 (Chae et al.,
2002).
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Although GR-fusions are very useful for inducing
gene expression, there is always the potential complica-
tion of interaction between endogenous GR signaling
and the exogenous fusion proteins. A second commonly
used system makes use of the tetracycline repressor
protein from E. coli. The tetracycline repressor (TetR)
protein recognizes the tetracycline operator (tetO/TRE)
sequence that can be used to drive gene expression. In
the presence of tetracycline, or its analogue doxycy-
cline, the repressor protein loses its affinity for the
target sequence resulting in loss of expression, or a
‘‘drug off’’ system. This system has also been modified
to a ‘‘drug on’’ system, where a mutant variant of the
repressor only binds to the target system in the pres-
ence of drug (rTtA). This approach is widely used in
mouse and has been adapted to Xenopus (Das and
Brown, 2004). However, this method has not been
exploited in Xenopus, in part due to the complexities
of maintaining transgenics. In addition, transgenic
approaches in other organisms, such as mouse, has
demonstrated that introduced DNA is often subject
to local effects, such as gene silencing or ‘‘leaky’’
expression due to nearby promoter elements (Clark
et al., 1994).
Most recently, Rankin et al. developed two versatile
Xenopus transgenic lines, one ubiquitously expressing
the doxycycline responsive rTtA and a second express-
ing the responsive TRE-promoter driving a construct
expressing an activated thyroid hormone receptor
(Rankin et al., 2011). These two lines are being made
available through the Xenopus Stock Centre (University
of Portsmouth, UK; see also Pearl et al., this issue). In
the future, they can be combined with additional lines
such as tissue-specific rTtA or TRE-promoters driving
other genes. A new library of efficient transgenesis tools
are also now available in Xenopus; these incorporate
GAL4-UAS, recombination capabilities and tissue speci-
ficity (Love et al., 2011). Furthermore, they could, in
principle, be used in combination with injection of
mRNA or plasmids expressing the drivers or targets.
Combining these approaches will improve specificity of
the transgenes while reducing ectopic or ‘‘leaky’’ effects.
Controlling translation with small molecules
For many years, developmental studies in Xenopus
were primarily limited to overexpression of DNAs,
mRNAs or proteins. As a result, determining the activity
of a protein was comparatively straightforward. It was
more difficult to assess the specific in vivo require-
ments. RNA-based strategies, such as short interfering
Table 3
Controlling Transcription With Small Molecules
Method Compound Reference
Hormone responsive transcription
Glucocorticoid receptor
(GR) fusion
Dexamethasone Kolm and
Sive, 1995
Estrogen receptor
(ER) fusion
b-estradiol
combined with engrailed
repressor
Dexamethasone Horb and
Thomsen 1999
combined with VP16
activation
Dexamethasone Rones et al., 2000
Bipartite GAL4/UAS
systems
GR-GAL4 fusion Dexamethasone Hartley et al., 2002
Progesterone receptor
(PR) fusion
Progesterone Chae et al., 2002
Bipartite tetracycline
repressor/operator
Tetracycline/ Das and Brown
2004
rTtA activator/TRE
promoter
Doxycycline Rankin et al., 2011
Light sensitive
transcriptional
activation
Photosensitive
doxycycline
Cambridge et al.,
2009
FIG. 2. Chemical control of transcription and translation. (A) The
ligand-binding domains of hormone receptors such as the gluco-
corticoid receptor (GR) can be fused to transcription factors. In the
absence of ligand, these chimeric proteins are sequestered by heat
shock protein-90 (HSP90). Ligand binding induces a conforma-
tional change, leading to release of the protein and subsequent
transcriptional activation. (B) Transgenic animals carrying two plas-
mids, one encoding the ‘‘driver,’’ a GR-GAL4 fusion, and the sec-
ond carrying the upstream activating sequence (UAS) ‘‘reporter,’’
driving expression of the target gene. A tissue-specific promoter
could be used to drive expression of the Gal4-GR fusion protein.
This process will allow for temporal and spatial control of expres-
sion. (C) Several antisense methods use synthetic oligonucleotides
to block translation. To improve the specificity of antisense mor-
pholino oligonucleotides (MOs), several groups have designed
caged MOs, which are unable to bind to their complementary tar-
get. Irradiation leads to uncaging and release of the MO, which is
then free to inhibit translation.
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RNAs, have been used to good effect in other systems
(Paddison et al., 2002). These methods have not
worked well in Xenopus. A recent study suggests that
this is due to a lack of the Argonaute-2 (Ago2) protein in
embryos. Ago2 is necessary for dicer dependent nucle-
ase activity and Lund et al. have shown that expression
of exogenous Ago2 is sufficient for RNAi activity in
Xenopus (Lund et al., 2011). However, for many years
RNAi seemed impossible in Xenopus; therefore, studies
in Xenopus have made use of synthetic nonnatural
oligonucleotides to target RNA activity, summarized in
Table 4.
In 2000, Heasman et al. showed that use of 25-base
antisense morpholino oligonucleotides (MOs) effi-
ciently blocked translation of target proteins, resulting
in loss-of-function phenotypes (Heasman et al., 2000).
These MOs contain a morpholino-phosphorodiamidate
backbone instead of a deoxyribose-phosphate backbone
and are therefore resistant to RNase H-degradation,
resulting in very stable interactions. Over the past dec-
ade, this use of synthetic antisense oligonucleotides to
induce loss-of-function phenotypes has become routine
in Xenopus (Tomlinson et al., 2008; Garcia-Morales
et al., 2009).
Several additional antisense approaches, which have
not been as broadly utilized, use the same strategy of
eluding RNase H-sensitivity. These include locked
nucleic acids (LNA) in which an extra link between the
20-O and the 40-C ‘‘locks’’ the ribose group, phosphoro-
thioate substituted nucleic acids (PS), peptide nucleic
acids (PNAs), in which the bases are linked to the back-
bone by methylene carbonyl bonds (Hanvey et al.,
1992; Obika et al., 2001; Wahlestedt et al., 2000; Woolf
et al., 1990) and fully modified 20-O-methyl oligonucleo-
tides (Schneider et al., 2011). Each of these methods
has been validated in Xenopus. A recent paper com-
pares the efficacy of knockdowns, suggesting that LNA
compounds are the most active and specific (Dodd
et al., 2011; Lennox et al., 2006). Thus, together with
MOs, Xenopus biologists have a range of methods to
regulate translation of target proteins. New refinements
such as photoactivation, described further below,
are improving the spatial and temporal resolution
of these methods (see below, and Fig. 2c) (Deiters
et al., 2010).
Controlling protein function with small
molecules
Methods that act on DNA and RNA are limited by the
cellular machinery and are dependent on RNA produc-
tion, translation and protein degradation rates. As
outlined above, the most rapid way to control gene func-
tion is to use small molecules that act directly on target
proteins, either by regulating protein availability, activity
or stability, uses in Xenopus summarized in Table 5.
Thus, it would be ideal to have generalizable approaches
such as the chemical targeting of kinases by the Shokat
and Ginty labs (Chen et al., 2005). One approach that
could be easily applied to many proteins is to use ligand-
dependent stabilization or degradation domains.
We and others have exploited several alternative
ways to control protein activity by fusing a destabilizing
peptide tag to the protein of interest. In the absence of
drug, the fusion protein is unstable and rapidly
degraded. The addition of drug restores protein stability
and function. We have previously used this system to
regulate GSK-3b in vivo (Liu et al., 2007). In this
approach, the peptide moiety, derived from the FK506/
rapamycin binding (FRB) domain, has been engineered
to be unstable in the absence of drug (Banaszynski
et al., 2006; Stankunas et al., 2003). The relevant drug
then acts as a ‘‘chemical chaperone’’ which restores
stability and function of the fusion protein (Fig. 3a).
Two additional systems have been developed using
directed evolution (error-prone PCR) to generate unsta-
ble variants of FKBP-12 (FKBP*) and dihydrofolate
reductase (DHFR*), (Banaszynski et al., 2006). These
systems have not yet been tested, and pharmacokinetics
and pharmacodynamics will need to be assessed.
Of the three systems, the original, derived from an
unstable variant of the FKBP-rapamycin binding motif
(FRB*), has been validated using a ‘‘knock in’’ strategy in
mouse, in which glycogen synthase kinase-3b (GSK-3b)
is replaced by a fusion protein, GSK-3bFRB* (see sche-
matic Fig. 3a, (Stankunas et al., 2003). In the absence of
rapamycin or rapamycin analogues, these mutant ani-
Table 4
Controlling Translation With Antisense Approaches
Method Oligos Reference
Antisense morpholino
oligonucleotides (MO)
Synthetic Heasman et al.,
2000
Antisense phosphorothioate
oligos
Modified Woolf et al., 1990
Various modified
oligonucleotides
Modified Lennox et al., 2006
locked nucleic acids
phosphorothioates
phosphoramidates
Peptide nucleic acids
(platinum conjugates)
Synthetic Dodd et al., 2011
20-O-methyl oligonucleotides Modified Schneider et al.,
2011
UV-activated morpholino
oligonucleotides
Synthetic Deiters et al., 2010
Table 5
Controlling Protein Function With Engineered Domains
Method Compound Reference
Inducible dimerization FK1012 Yang et al., 1998
Pownall et al., 2003
Inducible stabilization Rapamycin Liu et al., 2006
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mals are identical to conventional loss-of-function al-
leles; treatment with drug restores protein stability and
function, thus rescuing embryonic phenotypes (Liu
et al., 2007; Stankunas et al., 2003). Washout of the
drug or use of a competitive FK506-derived inhibitor
allows reversible on/off cycles of protein activity. To
avoid off-target effects, analogs of rapamycin and FK506
have been developed (MaRap and Shld-1, respectively).
Neither MaRap nor Shld-1 can bind to the natural targets
of the parental drugs (Banaszynski et al., 2006; Stanku-
nas et al., 2003).
We have also validated this approach in Xenopus
using expression of a chemically dependent luciferase
protein and found that stabilization of the target protein
was both dose-dependent, temperature-dependent and
reversible (Liu et al., 2006). Because the drugs directly
regulate stability, and hence availability, of the target
protein, this system affords much more rapid switching
of protein function than transcription-based methods
(e.g., Tet-on systems). Furthermore, conditional protein
stabilization via the small molecules Shld-1 or rapamycin
could be combined with tet-inducible systems to
decrease ‘‘leakiness’’ of the transcriptional activator
(Almogy and Nolan, 2009).
Finally, because the rapamycin or rapamycin ana-
logues induce dimerization of the FRB domain to the
FIG. 3. Chemically engineered control of protein interactions. (A) Target proteins are fused to a drug-sensitive destabilizing domain. In this
case, the target protein, GSK-3 is fused to the rapamycin binding domain FRB*. In the absence of drug, the fusion protein is unstable and
rapidly degraded. The addition of drug promotes dimerization with the chaperone protein FK506-binding protein (FKBP). This interaction
restores protein stability and function. (B) Similar drug–protein interactions can be used to regulate dimerization. In this schematic, the
rapamycin or rapamycin analogues induce dimerization of the FRB domain to FKBP. FKBP can be tagged with a subcellular tag, such as a
nuclear localization signal (NLS). In this scenario, the FRB*-tagged protein can be simultaneously stabilized and relocalized. (C) This
approach has been used successfully to induce dimerization of receptors such as insulin, platelet-derived growth factor (PDGF) and fibro-
blast growth factor receptors (FGF). Receptors are fused to the FKBP protein. Dimerization is then induced using a synthetic compound,
FK1012, which binds two molecules of FKBP with high affinity. Dimerization of these receptors leads to activation of signaling pathways in
the absence of endogenous ligands. (D) Heterodimerization of receptors, or cellular proteins, can also be induced using rapamycin, as in
(B). In this case, two different proteins are tagged with FKBP and FRB, respectively. Addition of rapamycin induces heterodimerization of
stoichiometric levels of protein (as opposed to tagging both proteins with FKBP, after (C).
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FK506-binding protein (FKBP), this system can also be
used to induce ligand-dependent dimerization (Fig. 3b).
In this case, the FRB*-tagged protein is simultaneously
stabilized and relocalized when coexpressed with FKBP
carrying a subcellular localization tag. This interaction
can be reversed using a competitive inhibitor, FK506M,
which binds to FKBP, dissociating the rapalogue. Varia-
tions on these systems have been used very successfully
to induce homodimerization or heterodimerization of
receptors (Fig. 3c,d, respectively), including insulin,
platelet-derived growth factor (PDGF) and fibroblast
growth factor receptors (FGFRs) in vivo (Pownall et al.,
2003; Yang et al., 1998).
We feel the frog would be ideal to rapidly test these
systems in parallel. Ideally, we would determine which
domain works the best for each target protein. It is also
conceivable that the three different destabilizing
domains could be used in parallel. For example, if we
had three different destabilized fusion proteins (X-FRB*,
Y-FKBP*, and Z-DHFR*), we could then use the three dif-
ferent drugs to control timing of three different protein
activities, within the same biological system. A long-
term application would then be the ability to do ‘‘order-
of-addition’’ experiments in any biological process.
Photoactivation reduces signal-to-noise
Precise spatial and temporal control of protein activ-
ity is notoriously difficult to achieve in vivo. However,
recently, a number of synthetic approaches make use of
photoswitchable compounds to refine chemical con-
trol. In these approaches, the chemically dependent
molecules could be introduced throughout the orga-
nism. These would remain quiescent until light-activa-
tion ‘‘uncages’’ the activating compounds. Because light
can be focused on single cells or specific tissues, these
approaches would allow fine control over spatiotempo-
ral protein activity. Xenopus is an ideal system for test-
ing and application of these systems, because they are
easy to microinject, develop ex utero, and are reason-
ably transparent as swimming tadpoles.
To provide a light-sensitive transcriptional control
system, Cambridge et al. recently designed two caged
analogues of tetracycline: caged doxycyline and caged
cyanodoxycline (Cambridge et al., 2009). The second
compound has the additional advantage of reduced
membrane permeability, to increase perdurance within
the cell after uncaging. Both compounds are soluble in
aqueous solutions and are activated at a wavelength of
330–350 nM, thus GFP excitation could be used as an
orthogonal system. Cambridge et al. went on to validate
these compounds in Xenopus using the existing tet-on
transgenics (Das and Brown, 2004). Therefore, these
compounds should be very useful for in vivo activation
of next generation Tet-dependent transgenes (Das and
Brown, 2004).
To improve the specificity of antisense morpholino
oligonucleotides, Shestapolov et al. designed MOs with
a short complementary blocking MO that is attached
with a photosensitive linker. Irradiation with 360-nm
light releases the short fragment, thus freeing the anti-
sense MO (Shestopalov et al., 2007). Although this
approach seems to work well in zebrafish, it does have
the disadvantage that one must synthesize two MOs, in
addition to coupling them together. Furthermore,
releasing the MOs results in two distinct MO molecules,
which could lead to toxicity or off target effects (Deiters
et al., 2010; Shestopalov et al., 2007). More recently,
Deiters et al. have designed a new caging approach for
MOs (Fig. 2c), (Deiters et al., 2010). They hypothesized
that incorporation of a photosensitive group, 6-nitropi-
peronyloxymethyl (NPOM), would first disrupt
DNA:RNA duplexes. NPOM could then be simply
removed by UV irradiation (at 365 nM). As a proof of
principle, they showed that they could readily target
expression of green fluorescent protein (expressed as
an mRNA) in a light-sensitive manner (Deiters et al.,
2010).
Finally, photoregulation of small molecules can allow
precise spatial and temporal control of signaling.
Morckel et al. reasoned that the addition of the NPOM
group to Rockout, a known Rho kinase inhibitor, would
render it photoactivatable (Morckel et al., 2012). They
then treated tadpoles, uncaging the compound on the
left versus the right side during gut morphogenesis.
These experiments revealed a specific right-sided
requirement for Rho kinase in gut looping. These excit-
ing new tools, which should be broadly generalizable,
demonstrate the power of combining chemical
approaches with developmental studies.
CONCLUSION
In summary, Xenopus is an excellent system for a vari-
ety of chemical screens. Tadpoles can be visually
assayed for morphological changes ranging from hetero-
taxia, body size and shape, melanocyte migration, skele-
tal development and organogenesis. By combining
chemical structure predictions and enzymatic assays
using Xenopus lysates, researchers can correlate pheno-
types with biochemical activities. Even more powerful,
chemical screens can be designed to utilize transgenic
animals or overexpression of target proteins. New tech-
nologies can also be readily assessed and refined in Xen-
opus, since overexpression and transgenic approaches
are routine and economical. All of these approaches
allow validation of drug–protein interactions, which
can be an extremely challenging part of drug discovery.
Finally, Xenopus as an in vivo system can provide great
insights into the pharmacology of identified compounds
as well as anticipating off-target effects (Vandenberg
et al., 2011).
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